She has more than 30 years of experience in the biotech and high-tech industries, with roles at Juno Therapeutics, Genentech/Roche, and Ariba.
Chimeric Therapeutics () has appointed biotech industry veteran Cindy Elkins as a non-executive director.
Elkins brings more than 30 years of experience in the biotech and high tech industries, with roles at Juno Therapeutics, Genentech/Roche, and Ariba
She also sat on the board of directors and audit committee for global wellness and weight loss company Weight Watchers for five years and is currently board chair of The Foundation for Art & Healing whose signature initiative is The UnLonely Project.
“Outstanding addition”
Chimeric’s executive chairman Paul Hopper said: “Cindy is an outstanding addition to Chimeric’s board of directors.
“Her long and successful career with renowned pharma businesses, specifically in the CAR T sector, will prove invaluable as we look to develop and commercialise our CLTX-CAR T asset.
“Chimeric’s CLTX-CAR T therapy, which uses a peptide derived from scorpion toxin to direct T cells to target glioblastoma (GBM), is currently being used in Phase 1 clinical trial at City of Hope to treat GBM.”
Previous roles
Elkins’ experience includes her role as executive vice president and chief information officer at Juno
Therapeutics, one of the pioneers in CAR T technology focused on blood cancers.
Her role evolved into the head of global CAR T Patient Experience, responsible for connecting patients with their personalised medicine through world-leading service and technology.
She created Juno Therapeutics global CAR T patient experience, connecting patients with their personalised medicine through world-leading service and technology.
Before Juno, Elkins was vice-president of pharma informatics at Genentech/Roche, where she was instrumental in ensuring all technology systems/processes were ready as soon as the FDA approved new medicines such as Zelboraf®, Gazyva®, Cotellic® and Tecentriq®.
Prior to Genentech, she was VP and General Manager at Ariba, where she created the largest transacting B2B eCommerce network in the world.
CLTX-CAR T therapy
Chimeric Therapeutics is developing ground-breaking CAR-T cell therapies for solid tumours based on scientific research conducted by leading US CAR-T experts at the City of Hope (COH) Cancer Centre in Los Angeles.
The company’s CLTX-CAR T therapy uses a peptide derived from scorpion toxin to direct T cells to target glioblastoma (GBM) – an aggressive form of brain cancer.
The treatment is being used in a Phase 1 clinical trial at COH to treat GBM where dosing of patients is underway, and the company is well funded and plans to conduct a patient study of 50 to 75 people following the completion of its phase one clinical trial.
Recent Comments